The 3 KEYNOTE-189 study has compared pembrolizumab, plus pemetrexed and platinum versus placebo plus pemetrexed-platinum as first-line therapy in patients with metastatic, non-squamous, non-small cell lung cancer.

The ADAURA study has evaluated osimertinib as adjuvant therapy in patients with stage IB to IIIA EGFR mutation-positive non-small cell lung cancer after complete resection.

At ASCO 2020, Martin Pitzzu et al., presented an Argentine study where a cohort of 300 prostate cancer patients were consecutively examined.

The results of the CheckMate-227 study showed that novolumab in compilation with ipilimumab for NSCLC continued to show durable and long-term efficacy benefits, including a significant overall survival rate, compared to chemo alone

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on survival.

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).